Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Phase 1 Completed 12 enrolled Institute of Hematology & Blood Diseases Hospital, China Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd. · collab

NaSequentialOpen-labelTreatment

Summary

This is an open-label, multicenter, dose-escalation phase 1 study to determine the safety and efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma.

Timeline

Start: 2018-06-08
Primary completion: 2021-06-04
Completion: 2021-06-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BZ019	Cell therapy	1e+06 cells/kg	—
Subject	BZ019	Cell therapy	3e+06 cells/kg	—
Subject	BZ019	Cell therapy	6e+06 cells/kg	—

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Summary

Timeline

Drugs

Indications